Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that CEO Dr. Klaus Paulini will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:00 AM EDT. The presentation will be accessible via a live webcast, which will also be archived for 90 days. The company focuses on developing therapeutics and diagnostic tests, notably Macrilen™, approved for diagnosing adult growth hormone deficiency.

- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16^th at 11:00 AM EDT -

CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna will present at the H.C. Wainwright 22^nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:00 AM EDT.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website here.

A live video webcast of the presentation will be available on the Events and Presentations page in the Investors section of the Company’s website (www.zentaris.com). The video webcast replay will be made available two hours following the event and will be archived for 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.

Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.

The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What date will the Aeterna Zentaris presentation take place?

The Aeterna Zentaris presentation will take place on September 16, 2020.

Who is presenting for Aeterna Zentaris at the conference?

Dr. Klaus Paulini, the CEO of Aeterna Zentaris, will be presenting at the conference.

What is the focus of Aeterna Zentaris?

Aeterna Zentaris focuses on commercializing and developing therapeutics and diagnostic tests.

What is Macrilen™ developed by Aeterna Zentaris?

Macrilen™ is the first FDA-approved oral test for diagnosing adult growth hormone deficiency.

How can I access the Aeterna Zentaris presentation?

You can access the presentation via a live webcast on the company’s website.

Is the Aeterna Zentaris presentation being archived?

Yes, the presentation will be archived and available for 90 days after the event.